{
    "ticker": "RYTM",
    "name": "Rhythm Pharmaceuticals, Inc.",
    "description": "Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative therapies for the treatment of rare genetic diseases of obesity. Founded in 2013 and headquartered in Boston, Massachusetts, Rhythm aims to address the unmet medical needs of patients suffering from these conditions, particularly through the modulation of the melanocortin system. The company's lead product candidate, setmelanotide, is designed to target the underlying causes of obesity in patients with specific genetic disorders, such as POMC deficiency and LEPR deficiency. Rhythm's mission is to improve the lives of patients by delivering effective treatments that can significantly enhance their quality of life. The company is committed to advancing its research and development efforts while building a strong pipeline of therapies. Rhythm collaborates with various healthcare professionals and advocacy groups to raise awareness about genetic obesity disorders and to further support patients in their treatment journeys. Through its dedication to science and patient-centric approaches, Rhythm Pharmaceuticals strives to be a leader in the field of genetic disease therapeutics.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Boston, Massachusetts, USA",
    "founded": "2013",
    "website": "https://www.rhythmtx.com",
    "ceo": "David Meeker",
    "social_media": {
        "twitter": "https://twitter.com/RhythmPharma",
        "linkedin": "https://www.linkedin.com/company/rhythm-pharmaceuticals"
    },
    "investor_relations": "https://investors.rhythmtx.com",
    "key_executives": [
        {
            "name": "David Meeker",
            "position": "CEO"
        },
        {
            "name": "Keith Gottesdiener",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Pharmaceuticals",
            "products": [
                "Setmelanotide"
            ]
        }
    ],
    "seo": {
        "meta_title": "Rhythm Pharmaceuticals, Inc. | Innovating Therapies for Genetic Obesity",
        "meta_description": "Learn about Rhythm Pharmaceuticals, Inc., a leader in developing therapies for rare genetic diseases of obesity. Discover our mission and product pipeline.",
        "keywords": [
            "Rhythm Pharmaceuticals",
            "Setmelanotide",
            "Genetic Obesity",
            "Biopharmaceuticals",
            "Healthcare"
        ]
    },
    "faq": [
        {
            "question": "What is Rhythm Pharmaceuticals known for?",
            "answer": "Rhythm Pharmaceuticals is known for developing innovative therapies for rare genetic diseases of obesity."
        },
        {
            "question": "Who is the CEO of Rhythm Pharmaceuticals?",
            "answer": "David Meeker is the CEO of Rhythm Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Rhythm Pharmaceuticals headquartered?",
            "answer": "Rhythm Pharmaceuticals is headquartered in Boston, Massachusetts, USA."
        },
        {
            "question": "What is Rhythm's lead product candidate?",
            "answer": "Rhythm's lead product candidate is setmelanotide."
        },
        {
            "question": "When was Rhythm Pharmaceuticals founded?",
            "answer": "Rhythm Pharmaceuticals was founded in 2013."
        }
    ],
    "competitors": [
        "NVS",
        "AMGN",
        "REGN",
        "VRTX"
    ],
    "related_stocks": [
        "PFE",
        "MRNA",
        "ABBV",
        "JNJ"
    ]
}